清润方对糖尿病大鼠肝脏SIRT/NF-κB信号通路的影响

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (583 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究清润方对2型糖尿病胰岛素抵抗大鼠肝脏内沉默调节蛋白（SIRT）/核因子κB（NF-κB）信号通路的影响。方法选取90只12周龄的Wistar雄性大鼠作为研究对象，其中15只作为正常组，其余75只采用脂肪乳灌胃30 d和腹腔注射链脲佐菌素（STZ）的方法建立2型糖尿病胰岛素抵抗模型。将造模成功的60只糖尿病大鼠按照随机数字表法随机分成模型组、二甲双胍组[250 mg/（kg·d）]、清润方大剂量组[11.2 g/（kg·d）]、清润方中剂量组[5.6 g/（kg·d）]和清润方小剂量组[2.8 g/（kg·d）]，每组12只。各组均灌胃给药，每天1次，连续8周。酶联免疫吸附测定（ELISA）法检测各组肝组织中肿瘤坏死因子α（TNF-α）和白细胞介素6（IL-6）的含量，qRT-PCR法和Western blot法检测肝组织中SIRT1、NF-κB和葡萄糖转运蛋白4（GLUT4）的mRNA和蛋白表达水平。结果与模型组比较，清润方大剂量组TNF-α水平降低（P ＜ 0.05），清润方大、中剂量组IL-6水平降低（P ＜ 0.05），清润方各剂量组SIRT1的mRNA和蛋白表达水平升高（P ＜ 0.05），清润方大、中剂量组GLUT4的mRNA和蛋白表达水平升高（P ＜ 0.05），清润方大、中剂量组NF-κB的mRNA和蛋白表达水平降低（P ＜ 0.05）。结论清润方可能通过促进糖尿病大鼠肝脏中SIRT1的表达，从而下调NF-κB的表达水平来改善胰岛素抵抗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邱宗林王秋虹孙丰卉王泽林兰▲

关键词 ：清润方, 2型糖尿病, 胰岛素抵抗, 沉默调节蛋白/核因子&kappa, B信号通路

Abstract：Objective To study the effect of Qingrun Formula on sirtuin (SIRT)/nuclear factor-κB (NF-κB) signal pathway in livers of rats with diabetes mellitus and insulin resistance. Methods Ninety 12-week old Wistar male rats were selected as objects, 15 rats were as normal group, the other 75 rats were induced by intraperitoneal injection of Streptozotocin (STZ) and gavage with fat milk for 30 days. After successful modeling, 60 rats with diabetes were randomly divided into model group, Metformin group [250 mg/(kg·d)], high dosage of Qingrun Formula group [11.2 g/(kg·d)], middle dosage of Qingrun Formula group [5.6 g/(kg·d)] and low dosage of Qingrun Formula group [2.8 g/(kg·d)], with 12 rats in each group. Each group was given medicine by gavage, once a day, lasting for 8 weeks. The levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in liver tissues of each group were tested by enzyme-linked immunosorbent assay (ELISA). The mRNA and protein expression levels of SIRT1, NF-κB and glucose transporter 4 (GLUT4) in liver tissues of each group were tested by qRT-PCR and Western blot. Results Compared with model group, the level of TNF-α decreased in high dosage of Qingrun Formula group (P ＜ 0.05), the level of IL-6 decreased in high and middle dosage of Qingrun Formula groups (P ＜ 0.05), the mRNA and protein expression levels of SIRT1 increased in each dosage of Qingrun Formula groups (P ＜ 0.05), the mRNA and protein expression levels of GLUT4 increased in high and middle dosage of Qingrun Formula groups (P ＜ 0.05), the mRNA and protein expression levels of NF-κB decreased in the high and middle dosage of Qingrun Formula groups (P ＜ 0.05). Conclusion Qingrun Formula may alleviate the insulin resistance by increasing the expression of SIRT1 and thereby decreasing the expression of NF-κB in the liver of diabetic rats.

Key words： Qingrun Formula Type 2 diabetes mellitus Insulin resistance Sirtuin/nuclear factor-κB signal pathway

基金资助:国家自然科学基金面上项目（81573792）。

通讯作者: ▲通讯作者

作者简介: 邱宗林（1983.10-），男，博士，博士后；研究方向：中医内分泌疾病。

引用本文:

邱宗林王秋虹孙丰卉王泽林兰▲. 清润方对糖尿病大鼠肝脏SIRT/NF-κB信号通路的影响[J]. 中国医药导报, 2018, 15(28): 4-7,12.
QIU Zonglin WANG Qiuhong SUN Fenghui WANG Ze LIN Lan▲. Effecf of Qingrun Formula on SIRT/NF-κB signal pathway in liver of diabetic rats. 中国医药导报, 2018, 15(28): 4-7,12.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I28/4

[1] 廖涌.中国糖尿病的流行病学现状及展望[J].重庆医科大学学报，2015，40（7）：1042-1045.
[2] 吴家睿.2型糖尿病发生发展的分子机制研究[J].生命科学，2006，18（5）：411-413.
[3] 庞健丽.2型糖尿病三型辨证规范与疗效评价指标的研究[D].北京：中国中医科学院，2009.
[4] 付莹坤，倪青，林兰.清润方对糖尿病大鼠血糖及脂代谢的影响[J].中国中医药信息杂志，2012，19（5）：30-31，35.
[5] Esser N，Paquot N，Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes，metabolic syndrome and cardiovascular disease [J]. Expert Opin Investig Drugs，2015， 24（3）：283-307.
[6] Odegaard JI，Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis [J]. Science，2013，339（6116）：172-177.
[7] Baud L，Fouqueray B，Philippe C，et al. Tumor necrosis factor alpha and mesangial cells [J]. Kidney Int，1992，41（3）：600-603.
[8] Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus：the liver disease of our age?[J]. World J Gastroenterol，2014，20（27）：9072-9089.
[9] Watson RT，Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation [J]. Recent Prog Horm Res，2001，56：175-193.
[10] Senn JJ，Klover PJ，Nowak IA，et al. Interleukin-6 induces cellular insulin resistance in hepatocytes [J]. Diabetes，2002，51（12）：3391-3399.
[11] 常化静，吴新荣，何羡霞，等.IKK/NF-KB信号通路与2型糖尿病及中药抗炎治疗[C]//广东省药学会.2014年广东省药师周大会论文集，2017：209-213.
[12] Guarani V，Deflorian G，Franco CA，et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase [J]. Nature，2011，473（7346）：234-238.
[13] Jeon BT，Kim KE，Heo RW，et al. Myeloid-specific deletion of SIRT1 increases hepatic steatosis and hypothalamic inflammation in mice fed a high-fat diet [J]. Metab Brain Dis，2014，29（3）：635-643.
[14] Cao Y，Jiang X，Ma H，et al. SIRT1 and insulin resistance [J]. J Diabetes Complications，2016，30（1）：178-183.
[15] Gilbert RE，Thai K，Advani SL，et al. SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes [J]. Diabetologia，2015，58（4）：819-827.
[16] Rosebeck S，Madden L，Jin X，et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-κB activation [J]. Science，2011，331（6016）：468-472.
[17] Dandona P，Aljada A，Chaudhuri A，et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity，diabetes，and inflammation [J]. Circulation，2005，111（11）：1448-1454.
[18] Wang S，Zhao Y，Xia N，et al. KPNβ1 promotes palmitate-induced insulin resistance via NF-κB signaling in hepatocytes [J]. J Physiol Biochem，2015，71（4）：763-772.
[19] Wei Y，Gao J，Qin L，et al. Tanshinone Ⅰ alleviates insulin resistance in type 2 diabetes mellitus rats through IRS-1 pathway [J]. Biomed Pharmacother，2017，93：352-358.
[20] Shinozaki S，Chang K，Sakai M，et al. Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65 [J]. Sci Signal，2014，7（351）：ra106.